Literature DB >> 1717195

Pharmacokinetics of rectal drug administration, Part I. General considerations and clinical applications of centrally acting drugs.

E van Hoogdalem1, A G de Boer, D D Breimer.   

Abstract

Generally, oral administration is the route of choice in the daily practice of pharmacotherapy. However, in some circumstances this is impractical or even impossible (during nausea and vomiting or convulsions, in uncooperative patients and before surgery). In these cases, the rectal route may represent a practical alternative and rectal administration is now well accepted for delivering, for example, anticonvulsants, non-narcotic and narcotic analgesics, theophylline, antiemetics and antibacterial agents, and for inducing anaesthesia in children. It may also represent an interesting alternative to intravenous or other injection routes of drug administration. The rate and extent of rectal drug absorption are often lower than with oral absorption, possibly an inherent factor owing to the relatively small surface area available for drug uptake. In addition, the composition of the rectal formulation (solid vs liquid, nature of the suppository base) appears to be an important factor in the absorption process by determining the pattern of drug release. This relation between formulation and drug uptake has been clearly demonstrated for drugs like diazepam, paracetamol (acetaminophen), indomethacin, methadone and diflunisal. Coadministration of absorption-promoting agents (surfactants, sodium salicylate, enamines) represents another approach towards manipulating rectal drug absorption, although this concept requires further research concerning both efficacy and safety. For a number of drugs the extent of rectal absorption has been reported to exceed oral values, which may reflect partial avoidance of hepatic first-pass metabolism after rectal delivery. This phenomenon has been reported for morphine, metoclopramide, ergotamine, lidocaine (lignocaine) and propranolol. Rectal drug delivery in a site- and rate-controlled manner using osmotic pumps or hydrogel formulations may provide opportunities for manipulating systemic drug concentrations and drug effects. The extent of first-pass metabolism may be influenced (lidocaine), depending on the site of drug administration in the rectum. The rate of delivery may determine systemic drug action and side effects (nifedipine), and it may affect the local action of concurrently administered absorption promoters on drug uptake (cefoxitin). Local irritation is increasingly being acknowledged as a possible complication of rectal drug therapy. Long term medication with rectal ergotamine and acetylsalicylic acid, for example, may result in rectal ulceration, and irritation after a single administration of several drugs and formulations has been described. The assessment of tolerability and safety is imperative in the design of rectal formulations. Recent studies corroborate the clinical relevance of rectal drug therapy, and the value of the rectal route as an alternative to parenteral administration has been assessed for several drugs, e.g. diazepam, midazolam, morphine and diclofenac.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1717195     DOI: 10.2165/00003088-199121010-00002

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  24 in total

1.  Intrarectal pharmacokinetics of two formulations of quinine in children with falciparum malaria.

Authors:  H Barennes; H Sterlingot; N Nagot; H Meda; M Kaboré; M Sanou; B Nacro; P Bourée; E Pussard
Journal:  Eur J Clin Pharmacol       Date:  2003-01-29       Impact factor: 2.953

2.  Pharmacokinetics and efficacy of rectal versus oral sustained-release morphine in cancer patients.

Authors:  T J Wilkinson; B A Robinson; E J Begg; S B Duffull; P J Ravenscroft; J J Schneider
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

3.  Rectal Metyrapone for Treatment of Hypercortisolism in an Infant with McCune-Albright Syndrome.

Authors:  Kate Verbeeten; Stasia Hadjiyannakis; Melody Cameron; Jaime McDonald
Journal:  J Pediatr Pharmacol Ther       Date:  2017 May-Jun

4.  Rectal and sublingual administration of tacrolimus: a single-dose pharmacokinetic study in healthy volunteers.

Authors:  Frank Stifft; Floris Vanmolkot; Ingrid Scheffers; Luc van Bortel; Cees Neef; Maarten Christiaans
Journal:  Br J Clin Pharmacol       Date:  2014-11       Impact factor: 4.335

5.  The relative bioavailability of metoprolol following oral and rectal administration to volunteers and patients.

Authors:  F M de Stoppelaar; L M Stolk; A J Beysens; J L Stappers; A P Gorgels
Journal:  Pharm World Sci       Date:  1999-10

6.  Dose-dependent resorption of quinine after intrarectal administration to children with moderate Plasmodium falciparum malaria.

Authors:  Eric Pussard; Celine Straczek; Idrissa Kaboré; Auguste Bicaba; Tatiana Balima-Koussoube; Patrice Bouree; Hubert Barennes
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

7.  Relative bioavailability, metabolism and tolerability of rectally administered oxcarbazepine suspension.

Authors:  Pamela L Clemens; James C Cloyd; Robert L Kriel; Rory P Remmel
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

8.  Clinical Pharmacokinetics of Cannabinoids and Potential Drug-Drug Interactions.

Authors:  Marta Vázquez; Carlos García-Carnelli; Cecilia Maldonado; Pietro Fagiolino
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

9.  Bioavailabilities of rectal and oral methadone in healthy subjects.

Authors:  Ola Dale; Pamela Sheffels; Evan D Kharasch
Journal:  Br J Clin Pharmacol       Date:  2004-08       Impact factor: 4.335

10.  Glucagon is absorbed from the rectum but does not hasten recovery from hypoglycaemia in patients with type 1 diabetes.

Authors:  David R Parker; Geoffrey D Braatvedt; Alexandra Bargiota; Paul G Newrick; Stephen Brown; Gregory Gamble; Roger J M Corrall
Journal:  Br J Clin Pharmacol       Date:  2008-05-27       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.